ALKS · XBRL financial data

Alkermes financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ALKS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	377*	350	399	378	430*	307	391	394	385*	393	496	480
Cost of goods and services sold	70*	59	61	63	62*	49	49	52	46*	62	98	94
Research and development	(21)*	68	60	60	58*	72	77	82	93*	103	113	121
Selling, general and administrative	141*	180	168	150	147*	172	171	172	187*	265	218	209
General and administrative	year only	54	48	48	48*	49	50	56	67*	109	63	—
Operating income (loss)	179*	43	110	105	163*	14	93	89	58*	(48)	18	36
Interest income	10*	9	11	11	11*	10	11	12	12*	9	5	6
Interest expense	6*	6	6	6	5*	0	0	0	12*	21	26	28
Other income (expense)	(0)*	0	2	1	0*	2	1	(0)	2*	(1)	0	(0)
Income tax expense (benefit)	(94)*	8	22	17	24*	3	18	18	11*	5	(2)	(2)
Net income (loss)	113*	37	91	92	147*	22	87	83	49*	(66)	1	16
Earnings per share, basic USD per share	0.68*	0.22	0.54	0.57	0.90*	0.14	0.53	0.50	0.30*	(0.40)	0.00	0.10
Earnings per share, diluted USD per share	0.66*	0.21	0.53	0.55	0.88*	0.13	0.52	0.49	0.29*	(0.40)	0.00	0.09
Weighted average shares, basic millions of shares	167*	168	168	163	162*	163	165	165	165*	166	167	168
Weighted average shares, diluted millions of shares	170*	173	171	167	166*	169	168	169	169*	166	173	176

Balance sheet

CSV

Fiscal quarters (ALKS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	457	421	535	396	291	400	521	616	389	352	512	631
Marketable securities	316	324	341	513	461	484	495	495	200	160	145	124
Marketable securities, non-current	38	61	86	19	73	32	38	28	—	26	35	32
Inventory	186	198	195	191	183	183	192	191	197	337	299	261
Prepaid and other current assets	98	112	101	94	91	90	71	84	79	102	111	105
Total current assets	1,486	1,469	1,542	1,564	1,415	1,479	1,635	1,742	1,929	1,359	1,523	1,581
Property and equipment, net	227	225	223	225	228	234	239	247	222	221	218	215
Right-of-use asset	91	90	88	86	84	82	81	79	77	78	76	80
Goodwill	83	83	83	83	83	—	—	—	83	596	594	593
Total assets	2,136	2,124	2,207	2,155	2,056	2,082	2,253	2,330	2,487	4,258	4,393	4,436
Accounts payable	66	77	105	37	46	60	99	68	108	102	143	108
Current portion of long-term debt	3	3	3	3	—	—	—	—	0	27	27	27
Total current liabilities	520	459	516	454	465	444	506	474	543	599	662	652
Long-term debt	288	287	286	286	—	—	—	—	0	1,484	1,477	1,471
Lease liability, non-current	76	74	73	71	69	68	66	65	63	64	62	66
Total liabilities	934	869	923	863	591	570	628	596	668	2,507	2,585	2,571
Accumulated deficit	(1,344)	(1,307)	(1,215)	(1,123)	(976)	(954)	(867)	(784)	(735)	(801)	(801)	(784)
Total stockholders' equity	1,203	1,255	1,284	1,292	1,465	1,512	1,625	1,733	1,819	1,752	1,809	1,865
Total liabilities and equity	2,136	2,124	2,207	2,155	2,056	2,082	2,253	2,330	2,487	4,258	4,393	4,436
Common shares outstanding (cover page) millions of shares	167	169	165	162	163	165	165	165	167	167	168	168

Cash flows

CSV

Fiscal quarters (ALKS's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	113*	37	91	92	147*	22	87	83	49*	(66)	1	16
Stock-based compensation	26*	33	21*	23*	21*	23	25*	25*	26*	36	31*	27*
Depreciation and amortization	19*	8	7*	7*	7*	7	8*	8*	4*	19	30*	27*
Net cash from operating activities	107*	21	146*	82*	190*	99	150*	102*	170*	(166)	145*	93*
Purchases of property and equipment	17*	8	7*	8*	10*	10	13*	17*	(0)*	4	8*	3*
Net cash from investing activities	(21)*	(40)	52*	(109)*	(14)*	9	(29)*	(7)*	322*	(2,077)	(2)*	20*
Share repurchases	—	—	—	116*	0*	—	—	0*	—	28	0*	0*
Repayments of long-term debt	1*	1	1*	1*	0*	—	—	0*	—	—	—	52*
Net cash from financing activities	(276)*	(18)	(83)*	(111)*	(282)*	1	0*	0*	11*	1,475	17*	6*
Net change in cash	(190)*	(37)	114*	(139)*	(105)*	109	121*	95*	503*	(768)	160*	120*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.